Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.Combination therapy for treatment of infections with gram-negative bacteria.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Carbapenems in the USA: focus on doripenem.Structure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.The efficacy and safety of antibiotic combination therapy for infections caused by Gram-positive and Gram-negative organisms.National Survey of Thai Infectious Disease Physicians on Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: The Role of Infection Control Awareness.In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
P2860
Q24612271-63C5BA1F-ACD0-41F9-9B56-06C4FE51C31FQ34327857-13FC0269-835C-46BC-B4A1-9CCF29038BDBQ35007624-D9CCE953-7A22-4A68-A71A-F76D45F139E7Q36156077-E58BF2C2-BEA6-4588-93D9-4B47D3E53A70Q36607415-2B574DD2-985A-4E43-8A37-47768C1DE5D7Q36960048-6B243EA1-5C23-4F48-B7C7-BC537E93B2A8Q37317645-2A59E22A-CADB-45B7-8D10-8EE4260E371AQ37949391-2DC1E233-053B-4AE8-9FD5-28687D1E2A63Q37954711-6E56CF54-0D49-4C3E-9DD4-F30BB3A615ADQ38383811-A7C73F18-0935-4B5F-9EC0-145C3DA4EB7AQ41337352-3DA8DF75-3249-439B-BA10-923AFDE36EC9Q46557679-16656E30-9033-449F-8C86-A08F2269E176
P2860
Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@en
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@nl
type
label
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@en
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@nl
prefLabel
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@en
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@nl
P2860
P356
P1476
Levofloxacin-imipenem combinat ...... tes of Pseudomonas aeruginosa.
@en
P2093
Daniel J Wolter
Philip D Lister
P2860
P304
P356
10.1086/426190
P407
P478
40 Suppl 2
P577
2005-02-01T00:00:00Z